Amgen Inc. ends 2025 on a high note. Thanks to strong sales of Repatha and Imdelltra, it raised its full-year 2025 revenue guidance from $35-$36 billion to $35.8-$36.6 billion. So, sales of Repatha, a ...

Please provide your email address to receive an email when new articles are posted on . The VESALIUS-CV trial evaluated the impact of the PCSK9 inhibitor evolocumab on risk for major adverse ...

MSD has fleshed out the results of phase 3 trials of its cholesterol-lowering, oral PCSK9 inhibitor, enlicitide decanoate, showing its efficacy was comparable to that of injectable alternatives. The ...

The White House announced it has signed nine new agreements with pharmaceutical companies Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis and Sanofi ...

Bristol Myers Squibb BMY and Amgen AMGN are among the largest global biotechnology companies with broad and diverse portfolios. Bristol Myers Squibb is focused on discovering, developing and ...

High cholesterol is one of the most common and manageable risk factors for heart disease. Millions of adults are prescribed cholesterol-lowering drugs to reduce low-density lipoprotein (LDL) ...

Q. My doctor prescribed rosuvastatin for high cholesterol. After taking it for six to nine months, I noticed that my cognitive function had slipped. I would not be able to find the word I was looking ...

Amgen highlighted its robust performance in 2024, achieving 14 products annualizing over $1 billion in sales. CEO Robert ...

TrumpRx is set to launch soon. President Donald Trump has been pressuring drug companies to lower prices. Americans currently pay about three times more for prescription medicine than patients in ...

If an ounce of prevention is worth a pound of cure, research in the primary and secondary prevention space in 2025 added up to sizeable gains when it comes to tackling atherosclerotic cardiovascular ...